贝伐单抗联合标准奥沙利铂方案治疗转移性大肠癌的效果观察  

Observation on the Effect of Bevacizumab Combined with Standard Oxaliplatin Regimen in the Treatment of Metastatic Colorectal Cancer

作　　者：戴强 费正华[2] 郑维锷 张武 DAI Qiang;FEI Zhenghua;ZHENG Wei’e;ZHANG Wu(Department of Medical Oncology,the Third Affiliated Hospital of Wenzhou Medical University,Wenzhou 325200,Zhejiang,China;Department of Chemotherapy,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325200,Zhejiang,China)

机构地区：[1]温州医科大学附属第三医院肿瘤内科,浙江温州325200 [2]温州医科大学附属第一医院放化疗科,浙江温州325000

出　　处：《中国药物滥用防治杂志》2023年第12期2126-2130,共5页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：瑞安市科技计划项目(编号:MS2020003)。

摘　　要：目的:探讨贝伐单抗联合标准奥沙利铂方案(FOLFOX-6)治疗转移性大肠癌(mCRC)的疗效。方法:选择2017年1月—2018年12月我院就诊的108例mCRC患者作为研究对象,采用随机数字表法将患者分为对照组和观察组,各54例。对照组采用FOLFOX-6方案化疗,观察组在对照组基础上给予贝伐单抗治疗。观察两组患者缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)和毒副反应。结果:观察组ORR和DCR均高于对照组,差异有统计学意义(P<0.05)。观察组PFS和OS均高于对照组,差异有统计学意义(P<0.05)。两组患者贫血、腹痛、腹泻、口腔黏膜炎、恶心、呕吐、疲劳、发烧、肝酶升高、血小板降低、白细胞降低等毒副反应发生率及≥Ⅲ度毒副反应发生率比较,差异无统计学意义(P>0.05)。观察组高血压发生率和≥Ⅲ度高血压发生率均高于对照组,差异有统计学意义(P<0.05)。结论:贝伐单抗联合标准FOLFOX-6方案可提高临床疗效,改善患者的PFS和OS,不增加化疗相关毒副反应发生率,但治疗期间需要严密监测患者血压变化。Objective:To investigate the efficacy of bevacizumab combined with standard oxaliplatin regimen(FOLFOX-6)in the treatment of metastatic colorectal cancer(mCRC).Methods:A total of 108 patients with mCRC who were treated in our hospital from January 2017 to December 2018 were selected as the research objects.The patients were divided into control group and observation group by random number table method,with 54 patients in each group.The control group was treated with FOLFOX-6 chemotherapy,and the observation group was treated with bevacizumab on the basis of the control group.The remission rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and side effects were observed in the two groups.Results:The ORR and DCR of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).The PFS and OS of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions such as anemia,abdominal pain,diarrhea,oral mucositis,nausea,vomiting,fatigue,fever,elevated liver enzymes,thrombocytopenia,leukopenia and the incidence of≥III degree adverse reactions between the two groups(P>0.05).The incidence of hypertension and the incidence of≥Ⅲdegree hypertension in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Bevacizumab combined with standard FOLFOX-6 regimen can improve the clinical efficacy,PFS and OS of patients,and does not increase the incidence of chemotherapy-related side effects,but the blood pressure changes of patients need to be closely monitored during treatment.

关 键 词：转移性大肠癌 贝伐单抗 FOLFOX-6方案 

分 类 号：R735.34[医药卫生—肿瘤]